新聞檔案

通過選擇所需的新聞類型,可以獲得最新的公告或演示文稿。

請使用 「新聞主題」進一步挑選公告類別。

所有公告的全文可以PDF文件的形式下載。 為方便起見,某些公告的部分或全部文字內容以網頁的方式呈現。 如存有任何不一致之處,請以PDF版本為準。

新聞類型
演示文稿
監管信息公告
新聞主題
創新平台
商業平台
監管通知
集團
1
23456789
找到相關結果: 429
London: Friday, November 29, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at November 29, 2019, the issued share capital of Chi-Med consisted of 666,886,450 ordinary shares of US$0.10 eac
閱讀更多
倫敦:2019年11月28日,星期四:和黃中國醫藥科技有限公司(簡稱「和黃醫藥」或「Chi-Med」)(AIM/Nasdaq: HCM)今天宣佈其用於治療晚期結直腸癌的國家1類靶向抗癌藥物愛優特®(呋喹替尼膠
閱讀更多
倫敦:2019年11月25日,星期一:和黃中國醫藥科技有限公司(簡稱「和黃醫藥」或「Chi-Med」) (AIM/Nasdaq: HCM) 今天宣佈索凡替尼獲美國食品藥品監督管理局(「FDA」)授予孤兒藥資格用於
閱讀更多
倫敦:2019年11月23日,星期六:和黃中國醫藥科技有限公司(簡稱「和黃醫藥」或「Chi-Med」) (AIM/Nasdaq: HCM) 將於2019年11月22日至24日在新加坡舉行的第五届歐洲腫瘤內科學會(「ESMO 」)
閱讀更多
倫敦:2019年11月11日,星期一:和黃中國醫藥科技有限公司(簡稱「和黃醫藥」或「Chi-Med」)(AIM/Nasdaq: HCM)今日宣布,中國國家藥品監督管理局(NMPA)已受理索凡替尼(surufatinib)用於治療
閱讀更多
倫敦,2019年10月17 日,星期四 :和黃中國醫藥科技有限公司 (簡稱“和黃醫藥”或“Chi-Med”) (AIM/納斯達克: HCM)今日重點介紹於美國癌症研究協會的期刊《癌症發現(Cancer Discovery)》[1] 發表
閱讀更多
London: Thursday, October 10, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that on October 9, 2019, it granted share options under the Share Option Scheme conditionally adopted by Chi-Med at its Annual General Me
閱讀更多
中國蘇州及英國倫敦,2019年10月10日,星期四:信達生物製藥(「信達生物」)(香港聯交所股票代碼:01801)與和黃中國醫藥科技有限公司(簡稱「和黃醫藥」或「Chi-Med」)(AIM/納斯達克
閱讀更多
倫敦,2019年10月4日,星期五:和黃中國醫藥科技有限公司(簡稱「和黃醫藥」或「Chi-Med」) (AIM/Nasdaq:HCM)啟動了一項HMPL-523治療復發性或難治性淋巴瘤患者的國際I/Ib期臨床試驗。HMPL-52
閱讀更多
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Hutch
閱讀更多
本新聞稿全部或部分內容的發布、刊發或派發,不得於或向或從任何視此等舉措屬違反當地有關法律的司法管轄區進行。 (本文件的中文本爲翻譯稿,僅供參考用。本文件的英文及中文版本
閱讀更多
本新聞稿全部或部分內容的發佈、刊發或派發,不得於或向或從任何視此等舉措屬違反當地有關法律的司法管轄區進行。 (本文件的中文本為翻譯稿,僅供參考用。本文件的英文及中文版
閱讀更多
London: Monday, September 30, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at September 30, 2019, the issued share capital of Chi-Med consisted of 666,786,450 ordinary shares of US$0.10 e
閱讀更多
– 索凡替尼在III期臨床試驗SANET-ep中達到了主要終點,幫助降低非胰腺神經內分泌瘤(「NET」)患者的疾病進展或死亡風險達67% – –目前正籌備計劃於2019年底前提交索凡替尼用於非胰腺神
閱讀更多
—即將發表關於索凡替尼治療非胰腺神經內分泌腫瘤患者的SANET-ep III期臨床試驗積極結果的最新摘要— —將於9月30日(星期一)聯同試驗主要研究者舉行電話會議和網絡音頻直播,共同解
閱讀更多
倫敦:2019年9月18日(星期三):和黃中國醫藥科技有限公司(簡稱「和黃醫藥」或「Chi-Med」) (AIM/Nasdaq:HCM) 將於2019年9月18-22日在中國廈門舉行的第22屆全國臨床腫瘤學大會暨2019年CSCO學
閱讀更多
倫敦:2019年9月3日(星期二):和黃中國醫藥科技有限公司(簡稱和黃醫藥“Chi-Med”)(AIM/納斯達克:HCM)今日宣佈,首席執行官Christian Hogg將於2019年9月11日星期三上午9點55分(美國東部時間)
閱讀更多
倫敦,2019年9月3日(星期二):和黃中國醫藥科技有限公司(簡稱和黃醫藥「Chi-Med」) (AIM/Nasdaq:HCM) 啟動了一項HMPL-689治療復發性或難治性淋巴瘤患者的國際I/Ib期臨床試驗。 HMPL-689是一種作
閱讀更多
London: Friday, August 30, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at August 30, 2019, the issued share capital of Chi-Med consisted of 666,777,450 ordinary shares of US$0.10 each, w
閱讀更多
倫敦,2019年8月23日 (星期五):和黃中國醫藥科技有限公司 (簡稱 「和黃醫藥」 或「Chi-Med」) (AIM/Nasdaq: HCM) 在中國啟動了一項HMPL-523治療免疫性血小板減少性紫癜 (「ITP」) 患者的I期臨床試驗
閱讀更多
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Hut
閱讀更多
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Hut
閱讀更多
倫敦:2019年7月30日(星期二): 和黃中國醫藥科技有限公司(Chi-Med)(AIM /納斯達克股票代碼: HCM)今天公佈截至2019年6月30日的未經審核財務數據,並公佈了關鍵臨床項目的最新進展。重點包
閱讀更多
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Hutch
閱讀更多
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Hut
閱讀更多
London: Wednesday, July 3, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will be announcing its interim results for the six months ended June 30, 2019 on Tuesday, July 30, 2019 at 7:00 am British Summer Time (BST) (2:00 pm
閱讀更多
London: June 28, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces the upsizing and pricing of the underwritten public secondary offering previously announced by Chi-Med on June 27, 2019. Hutchison Healthcare Holdings
閱讀更多
London: June 27, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that Hutchison Healthcare Holdings Limited (“HHHL”), the largest shareholder of Chi-Med and a subsidiary of CK Hutchison Holdings Limited (SEHK: 1
閱讀更多
香港:2019 年6 月14 日,星期五:和黃中國醫藥科技有限公司(Chi-Med)(AIM /納斯達克股票代碼:HCM)今日宣布索凡替尼以晚期非胰腺神經內分泌瘤為適應症的III 期關鍵性研究SANET-ep 預設的
閱讀更多
London: Wednesday, June 12, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that the following applications have been made to the London Stock Exchange plc for the block admission of ordinary shares, par value
閱讀更多
London: Thursday, June 6, 2019: Hutchison China MediTech Limited (“Chi-Med” or the “Company”) (AIM/Nasdaq: HCM) today filed the Post Hearing Information Pack (the “PHIP”) with the Stock Exchange of Hong Kong Limited (“SEHK”) in connec
閱讀更多
London: Wednesday, May 29, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that the ordinary resolution and special resolution put to its Extraordinary General Meeting (“EGM”) held on May 29, 2019 were dul
閱讀更多
London: Wednesday, May 22, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that on May 21, 2019, it granted share options under the Share Option Scheme conditionally adopted by Chi-Med at its Annual General Meeting
閱讀更多
London: Friday, May 3, 2019: Hutchison China MediTech Limited (“Chi-Med” or “Company”) (AIM/Nasdaq: HCM) today announces that an Extraordinary General Meeting (“EGM”) is to be held at 11:00 a.m. London time on Wednesday, May 29, 2019. An
閱讀更多
London: Wednesday, April 24, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that all ordinary resolutions and special resolutions put to its Annual General Meeting (“AGM”) held on April 24, 2019 were duly
閱讀更多
London: Monday, April 15, 2019: Hutchison China MediTech Limited (“Chi-Med” or the “Company”) (AIM/Nasdaq: HCM) today filed an application (the “Listing Application”) with the Stock Exchange of Hong Kong Limited (“SEHK”) in connection
閱讀更多
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Hong Kong: Monday, April 15, 2019: Hutchison China MediTech
閱讀更多
2019年3月29日,中國上海 — 和黃中國醫藥科技有限公司(Chi-Med)(AIM/NASDAQ: HCM)子公司和記黃埔醫藥在中國啟動了一項有註冊性潛力的IIb/III期臨床試驗,旨在對比索凡替尼(HMPL-012或sulfat
閱讀更多
2019年3月28日,中國上海 — 和黃中國醫藥科技有限公司 (Chi-Med)(AIM/NASDAQ: HCM) 子公司和記黃埔醫藥將於2019年3月31日-4月3日在美國佐治亞州亞特蘭大市召開的美國癌症研究協會(AACR)
閱讀更多
London: Monday, March 25, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that following the publication of the 2018 annual report of Chi-Med on March 21 2019, the following awards granted under the Long Term Incent
閱讀更多
London: Thursday, March 21, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that its 2018 Annual Report together with the Notice of Annual General Meeting and the Form of Proxy have been posted to shareholders
閱讀更多
London: Monday, March 11, 2019: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today published the Form 20-F for the financial year ended December 31, 2018. This is available for viewing at http://www.rns-pdf.londonstockexchange.com/r
閱讀更多
London: Monday, March 11, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces its audited financial results for the year ended December 31, 2018 and provides updates on key clinical programs. Video webcas
閱讀更多
香港:2019年2月12日,星期二:和黃中國醫藥科技有限公司 (Chi-Med)(AIM/NASDAQ: HCM)今日宣佈CALYPSO II期臨床研究中探索沃利替尼/Imfinzi®(durvalumab)聯合療法治療轉移性乳頭狀腎細胞癌(PRCC
閱讀更多
London: Friday, February 8, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will announce its final results for the year ended December 31, 2018 on Monday, March 11, 2019 at 7:00 am Greenwich Mean Time (GMT). An analyst pr
閱讀更多
Press Release London: Monday, January 7, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Christian Hogg, Chief Executive Officer, will present at the 37th Annual JP Morgan Healthcare Conference on Wednes
閱讀更多
London: Monday, December 31, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return: 1. Name of applicant: Hutchison China MediTech Limited 2. Name of scheme: (
閱讀更多
London: Monday, December 31, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at December 31, 2018, the issued share capital of Chi-Med consisted of 66,657,745 ordinary shares of US$1.00 each
閱讀更多
– Chi-Med acquires right to determine & conduct all future life cycle indication development of fruquintinib monotherapy as well as innovative combinations in China –  – Chi-Med to assume all development costs of life cycle indications in
閱讀更多
– Global SAVANNAH study of savolitinib / Tagrisso®combination in MET+ EGFRm NSCLC underway. Data presented at ESMO 2018 showedMET-amplification among the most frequent mechanisms of acquired resistance to AstraZeneca’s Tagrisso® – – China
閱讀更多